Shares of ResMed (RMD) have been strong performers lately, with the stock up 7.1% over the past month. The stock hit a new 52-week high of $260.49 in the previous session. ResMed has gained 48.9% since the start of the year compared to the 5.1% move for the Zacks Medical sector and the 12.8% return for the Zacks Medical - Products industry.

What's Driving the Outperformance?

The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on October 24, 2024, ResMed reported EPS of $2.2 versus consensus estimate of $2.03 while it beat the consensus revenue estimate by 2.98%.

For the current fiscal year, ResMed is expected to post earnings of $9.16 per share on $5.03 billion in revenues. This represents a 18.65% change in EPS on a 7.43% change in revenues. For the next fiscal year, the company is expected to earn $9.94 per share on $5.36 billion in revenues. This represents a year-over-year change of 8.49% and 6.41%, respectively.

Valuation Metrics

ResMed may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company has run ahead of itself.

On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. Investors should consider the style scores a valuable tool that can help you to pick the most appropriate Zacks Rank stocks based on their individual investment style.

ResMed has a Value Score of C. The stock's Growth and Momentum Scores are A and A, respectively, giving the company a VGM Score of A.

In terms of its value breakdown, the stock currently trades at 28X current fiscal year EPS estimates, which is a premium to the peer industry average of 22.2X. On a trailing cash flow basis, the stock currently trades at 27.8X versus its peer group's average of 12.5X. Additionally, the stock has a PEG ratio of 2.05. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.

Zacks Rank

We also need to look at the Zacks Rank for the stock, as this supersedes any trend on the style score front. Fortunately, ResMed currently has a Zacks Rank of #2 (Buy) thanks to favorable earnings estimate revisions from covering analysts.